Theratechnologies Inc.(THTX)

POST2.470.53+27.32%19:59 EDT

1.94+0.61+45.86%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

Company Profile
Company Name
Theratechnologies Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.theratech.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
- 02-26
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-04-17
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-02-21
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-14
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2024-02-07
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2024-01-02
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-11-29
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-11-28
  Beneficial Ownership Change
  Form SC 13D - General statement of acquisition of beneficial ownership
  Form SC 13D - General statement of acquisition of beneficial ownership
- 2023-11-13
  Beneficial Ownership Change
  Form SC 13D - General statement of acquisition of beneficial ownership
  Form SC 13D - General statement of acquisition of beneficial ownership
- 2023-02-27
  Annual Report
  40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
  40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
- 2023-02-13
  Beneficial Ownership Change
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2022-11-13
  Beneficial Ownership Change
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2022-02-23
  Annual Report
  40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
  40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
- 2022-02-09
  Beneficial Ownership Change
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2022-02-09
  Beneficial Ownership Change
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals

1D
5D
Day
Week
Month

Loading ...

High

2.29

Open

1.32

Volume%

94.52

Low

1.26

1.33

T/O Rate

141.39%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Theratechnologies Inc.(THTX)

Company Profile